Clinical Trial

Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy

Enrolling by Invitation Phase 4
View on ClinicalTrials.gov →
Summary
In this phase IV, randomized, double-masked, sham-controlled study the investigators hope to determine the efficacy in peri-operative faricimab (Vabysmo) compared to sham in limiting complications from pars plana vitrectomy for diabetic vitreous hemorrhage with or without tractional retinal detachments.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-12-19; most recent amendment 2026-05-28.
Status change: Not Yet Recruiting → Enrolling by Invitation 2024-08-01
Trial Details
NCT Number NCT06191094
Lead Sponsor University of Colorado, Denver
Conditions Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus
Enrollment 100 participants
Start Date 2024-07-12
Primary Completion 2026-12 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-01